$-0.73 EPS Expected for Cidara Therapeutics, Inc. (CDTX); Junto Capital Management LP Increased By $449,826 Its D R Horton (DHI) Holding

February 20, 2018 - By Migdalia James

Junto Capital Management Lp increased D R Horton Inc (DHI) stake by 1.34% reported in 2017Q3 SEC filing. Junto Capital Management Lp acquired 11,534 shares as D R Horton Inc (DHI)’s stock rose 10.82%. The Junto Capital Management Lp holds 872,034 shares with $34.82 million value, up from 860,500 last quarter. D R Horton Inc now has $17.17 billion valuation. The stock increased 0.22% or $0.1 during the last trading session, reaching $45.67. About 378,554 shares traded. D.R. Horton, Inc. (NYSE:DHI) has risen 15.56% since February 20, 2017 and is uptrending. It has underperformed by 1.14% the S&P500.

Analysts expect Cidara Therapeutics, Inc. (NASDAQ:CDTX) to report $-0.73 EPS on March, 21.They anticipate $0.15 EPS change or 17.05% from last quarter’s $-0.88 EPS. After having $-0.73 EPS previously, Cidara Therapeutics, Inc.’s analysts see 0.00% EPS growth. It closed at $6.95 lastly. It is down 38.96% since February 20, 2017 and is downtrending. It has underperformed by 55.66% the S&P500.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. The company has market cap of $140.66 million. The Company’s lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. It currently has negative earnings. The firm also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid.

Among 6 analysts covering Cidara Therapeutics (NASDAQ:CDTX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Cidara Therapeutics had 13 analyst reports since October 9, 2015 according to SRatingsIntel. H.C. Wainwright initiated Cidara Therapeutics, Inc. (NASDAQ:CDTX) rating on Monday, December 19. H.C. Wainwright has “Buy” rating and $25 target. On Wednesday, December 21 the stock rating was reinitiated by Leerink Swann with “Outperform”. Cantor Fitzgerald maintained it with “Buy” rating and $1500 target in Friday, June 23 report. Needham maintained it with “Buy” rating and $10.0 target in Tuesday, October 3 report. On Friday, October 9 the stock rating was upgraded by WBB Securities to “Hold”. The rating was downgraded by WBB Securities to “Sell” on Friday, September 23. H.C. Wainwright maintained it with “Buy” rating and $16 target in Thursday, November 9 report. The firm has “Buy” rating given on Thursday, August 10 by Cantor Fitzgerald. The stock has “Buy” rating by Cantor Fitzgerald on Monday, June 5. WBB Securities downgraded Cidara Therapeutics, Inc. (NASDAQ:CDTX) on Friday, July 28 to “Sell” rating.

Since September 8, 2017, it had 0 insider purchases, and 12 sales for $2.90 million activity. On Monday, February 12 the insider HORTON DONALD R sold $520,554. BUCHANAN MICHAEL R sold $333,564 worth of stock or 9,000 shares. WHEAT BILL W sold $120,181 worth of stock or 2,670 shares. $144,454 worth of D.R. Horton, Inc. (NYSE:DHI) shares were sold by Hewatt Michael W. 10,000 shares were sold by ANDERSON BRADLEY S, worth $374,629 on Wednesday, September 13. Auld David V also sold $224,384 worth of D.R. Horton, Inc. (NYSE:DHI) on Monday, February 12. Another trade for 3,667 shares valued at $175,158 was made by Allen Barbara K on Thursday, February 1.

Junto Capital Management Lp decreased Planet Fitness Inc stake by 248,949 shares to 1.35 million valued at $36.32M in 2017Q3. It also reduced Blackrock Inc (NYSE:BLK) stake by 40,968 shares and now owns 176,197 shares. Restaurant Brands Intl Inc was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: